nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS2—Etoposide—sarcoma	0.0473	0.542	CbGbCtD
Mesalazine—PTGS1—Etoposide—sarcoma	0.0399	0.458	CbGbCtD
Mesalazine—PPARG—dermis—sarcoma	0.013	0.0623	CbGeAlD
Mesalazine—PPARG—periosteum—sarcoma	0.0108	0.0516	CbGeAlD
Mesalazine—PPARG—leg—sarcoma	0.00859	0.0411	CbGeAlD
Mesalazine—PPARG—forelimb—sarcoma	0.00853	0.0408	CbGeAlD
Mesalazine—PPARG—hindlimb—sarcoma	0.00767	0.0367	CbGeAlD
Mesalazine—PPARG—appendage—sarcoma	0.00658	0.0315	CbGeAlD
Mesalazine—PPARG—Teniposide—Etoposide—sarcoma	0.00609	1	CbGdCrCtD
Mesalazine—PTGS2—periosteum—sarcoma	0.00551	0.0264	CbGeAlD
Mesalazine—CHUK—hematopoietic system—sarcoma	0.00461	0.0221	CbGeAlD
Mesalazine—MPO—endothelium—sarcoma	0.00448	0.0214	CbGeAlD
Mesalazine—CHUK—connective tissue—sarcoma	0.00444	0.0213	CbGeAlD
Mesalazine—PTGS2—leg—sarcoma	0.00439	0.021	CbGeAlD
Mesalazine—CHUK—skin of body—sarcoma	0.00401	0.0192	CbGeAlD
Mesalazine—PPARG—endothelium—sarcoma	0.00397	0.019	CbGeAlD
Mesalazine—PTGS2—hindlimb—sarcoma	0.00392	0.0188	CbGeAlD
Mesalazine—PTGS2—cartilage tissue—sarcoma	0.00386	0.0185	CbGeAlD
Mesalazine—IKBKB—myometrium—sarcoma	0.00365	0.0175	CbGeAlD
Mesalazine—IKBKB—embryo—sarcoma	0.00351	0.0168	CbGeAlD
Mesalazine—PTGS2—appendage—sarcoma	0.00336	0.0161	CbGeAlD
Mesalazine—CHUK—lymphoid tissue—sarcoma	0.00325	0.0156	CbGeAlD
Mesalazine—PPARG—mammary gland—sarcoma	0.0032	0.0153	CbGeAlD
Mesalazine—IKBKB—hematopoietic system—sarcoma	0.00314	0.015	CbGeAlD
Mesalazine—IKBKB—connective tissue—sarcoma	0.00302	0.0145	CbGeAlD
Mesalazine—IKBKB—smooth muscle tissue—sarcoma	0.00276	0.0132	CbGeAlD
Mesalazine—IKBKB—skin of body—sarcoma	0.00273	0.0131	CbGeAlD
Mesalazine—ALOX5—hematopoietic system—sarcoma	0.0026	0.0124	CbGeAlD
Mesalazine—CHUK—testis—sarcoma	0.00253	0.0121	CbGeAlD
Mesalazine—ALOX5—connective tissue—sarcoma	0.0025	0.012	CbGeAlD
Mesalazine—CHUK—liver—sarcoma	0.00239	0.0114	CbGeAlD
Mesalazine—IKBKB—uterus—sarcoma	0.00237	0.0113	CbGeAlD
Mesalazine—ALOX5—smooth muscle tissue—sarcoma	0.00229	0.011	CbGeAlD
Mesalazine—IKBKB—lymphoid tissue—sarcoma	0.00221	0.0106	CbGeAlD
Mesalazine—MPO—hematopoietic system—sarcoma	0.0022	0.0105	CbGeAlD
Mesalazine—PPARG—embryo—sarcoma	0.00219	0.0105	CbGeAlD
Mesalazine—PTGS1—endothelium—sarcoma	0.00212	0.0102	CbGeAlD
Mesalazine—MPO—connective tissue—sarcoma	0.00212	0.0101	CbGeAlD
Mesalazine—IKBKB—tendon—sarcoma	0.00207	0.00994	CbGeAlD
Mesalazine—PTGS2—endothelium—sarcoma	0.00203	0.00972	CbGeAlD
Mesalazine—PPARG—hematopoietic system—sarcoma	0.00195	0.00934	CbGeAlD
Mesalazine—MPO—skin of body—sarcoma	0.00191	0.00915	CbGeAlD
Mesalazine—PPARG—connective tissue—sarcoma	0.00188	0.009	CbGeAlD
Mesalazine—CHUK—lymph node—sarcoma	0.00183	0.00878	CbGeAlD
Mesalazine—ALOX5—lymphoid tissue—sarcoma	0.00183	0.00876	CbGeAlD
Mesalazine—PPARG—smooth muscle tissue—sarcoma	0.00172	0.00823	CbGeAlD
Mesalazine—IKBKB—testis—sarcoma	0.00172	0.00823	CbGeAlD
Mesalazine—PPARG—skin of body—sarcoma	0.0017	0.00812	CbGeAlD
Mesalazine—ALOX5—bone marrow—sarcoma	0.00167	0.00798	CbGeAlD
Mesalazine—IKBKB—liver—sarcoma	0.00162	0.00778	CbGeAlD
Mesalazine—MPO—lymphoid tissue—sarcoma	0.00155	0.00741	CbGeAlD
Mesalazine—PPARG—uterus—sarcoma	0.00147	0.00706	CbGeAlD
Mesalazine—ALOX5—testis—sarcoma	0.00142	0.00682	CbGeAlD
Mesalazine—MPO—bone marrow—sarcoma	0.00141	0.00675	CbGeAlD
Mesalazine—PPARG—lymphoid tissue—sarcoma	0.00137	0.00658	CbGeAlD
Mesalazine—ALOX5—liver—sarcoma	0.00135	0.00645	CbGeAlD
Mesalazine—PPARG—tendon—sarcoma	0.00129	0.00618	CbGeAlD
Mesalazine—PPARG—bone marrow—sarcoma	0.00125	0.00599	CbGeAlD
Mesalazine—IKBKB—lymph node—sarcoma	0.00125	0.00596	CbGeAlD
Mesalazine—MPO—testis—sarcoma	0.0012	0.00577	CbGeAlD
Mesalazine—PTGS2—myometrium—sarcoma	0.00116	0.00556	CbGeAlD
Mesalazine—MPO—liver—sarcoma	0.00114	0.00546	CbGeAlD
Mesalazine—PTGS2—embryo—sarcoma	0.00112	0.00535	CbGeAlD
Mesalazine—PTGS1—seminal vesicle—sarcoma	0.0011	0.00526	CbGeAlD
Mesalazine—PPARG—testis—sarcoma	0.00107	0.00512	CbGeAlD
Mesalazine—PTGS2—seminal vesicle—sarcoma	0.00105	0.00502	CbGeAlD
Mesalazine—PTGS1—hematopoietic system—sarcoma	0.00104	0.005	CbGeAlD
Mesalazine—ALOX5—lymph node—sarcoma	0.00103	0.00494	CbGeAlD
Mesalazine—PPARG—liver—sarcoma	0.00101	0.00484	CbGeAlD
Mesalazine—PTGS1—connective tissue—sarcoma	0.001	0.00481	CbGeAlD
Mesalazine—PTGS2—hematopoietic system—sarcoma	0.000997	0.00477	CbGeAlD
Mesalazine—PTGS2—connective tissue—sarcoma	0.00096	0.0046	CbGeAlD
Mesalazine—PTGS1—smooth muscle tissue—sarcoma	0.000919	0.0044	CbGeAlD
Mesalazine—PTGS1—skin of body—sarcoma	0.000907	0.00434	CbGeAlD
Mesalazine—PTGS2—smooth muscle tissue—sarcoma	0.000878	0.00421	CbGeAlD
Mesalazine—MPO—lymph node—sarcoma	0.000873	0.00418	CbGeAlD
Mesalazine—PTGS2—skin of body—sarcoma	0.000867	0.00415	CbGeAlD
Mesalazine—PTGS1—cardiac atrium—sarcoma	0.000792	0.00379	CbGeAlD
Mesalazine—PTGS1—uterus—sarcoma	0.000788	0.00377	CbGeAlD
Mesalazine—PPARG—lymph node—sarcoma	0.000775	0.00371	CbGeAlD
Mesalazine—PTGS2—uterus—sarcoma	0.000753	0.00361	CbGeAlD
Mesalazine—PTGS2—lymphoid tissue—sarcoma	0.000702	0.00336	CbGeAlD
Mesalazine—PTGS1—tendon—sarcoma	0.00069	0.00331	CbGeAlD
Mesalazine—PTGS2—tendon—sarcoma	0.00066	0.00316	CbGeAlD
Mesalazine—PTGS2—bone marrow—sarcoma	0.000639	0.00306	CbGeAlD
Mesalazine—PTGS1—testis—sarcoma	0.000572	0.00274	CbGeAlD
Mesalazine—PTGS2—liver—sarcoma	0.000516	0.00247	CbGeAlD
Mesalazine—PTGS1—lymph node—sarcoma	0.000414	0.00198	CbGeAlD
Mesalazine—PTGS2—lymph node—sarcoma	0.000396	0.0019	CbGeAlD
Mesalazine—Angina pectoris—Doxorubicin—sarcoma	0.000233	0.000581	CcSEcCtD
Mesalazine—Hypersensitivity—Mitoxantrone—sarcoma	0.000232	0.000579	CcSEcCtD
Mesalazine—Asthenia—Vincristine—sarcoma	0.000232	0.000579	CcSEcCtD
Mesalazine—Vomiting—Thiotepa—sarcoma	0.000232	0.000579	CcSEcCtD
Mesalazine—Pneumonia—Epirubicin—sarcoma	0.000232	0.000578	CcSEcCtD
Mesalazine—Infestation NOS—Epirubicin—sarcoma	0.00023	0.000575	CcSEcCtD
Mesalazine—Infestation—Epirubicin—sarcoma	0.00023	0.000575	CcSEcCtD
Mesalazine—Vomiting—Dactinomycin—sarcoma	0.00023	0.000575	CcSEcCtD
Mesalazine—Rash—Thiotepa—sarcoma	0.00023	0.000574	CcSEcCtD
Mesalazine—Bronchitis—Doxorubicin—sarcoma	0.00023	0.000574	CcSEcCtD
Mesalazine—Dermatitis—Thiotepa—sarcoma	0.00023	0.000574	CcSEcCtD
Mesalazine—Headache—Thiotepa—sarcoma	0.000228	0.00057	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000228	0.00057	CcSEcCtD
Mesalazine—Rash—Dactinomycin—sarcoma	0.000228	0.00057	CcSEcCtD
Mesalazine—Decreased appetite—Etoposide—sarcoma	0.000228	0.000569	CcSEcCtD
Mesalazine—Pancytopenia—Doxorubicin—sarcoma	0.000227	0.000567	CcSEcCtD
Mesalazine—Renal failure—Epirubicin—sarcoma	0.000226	0.000565	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Etoposide—sarcoma	0.000226	0.000565	CcSEcCtD
Mesalazine—Asthenia—Mitoxantrone—sarcoma	0.000226	0.000564	CcSEcCtD
Mesalazine—Fatigue—Etoposide—sarcoma	0.000226	0.000564	CcSEcCtD
Mesalazine—Neuropathy peripheral—Epirubicin—sarcoma	0.000226	0.000564	CcSEcCtD
Mesalazine—Stomatitis—Epirubicin—sarcoma	0.000224	0.00056	CcSEcCtD
Mesalazine—Jaundice—Epirubicin—sarcoma	0.000224	0.00056	CcSEcCtD
Mesalazine—Pain—Etoposide—sarcoma	0.000224	0.000559	CcSEcCtD
Mesalazine—Constipation—Etoposide—sarcoma	0.000224	0.000559	CcSEcCtD
Mesalazine—Conjunctivitis—Epirubicin—sarcoma	0.000224	0.000559	CcSEcCtD
Mesalazine—Urinary tract infection—Epirubicin—sarcoma	0.000224	0.000559	CcSEcCtD
Mesalazine—Neutropenia—Doxorubicin—sarcoma	0.000223	0.000558	CcSEcCtD
Mesalazine—Dysuria—Doxorubicin—sarcoma	0.000223	0.000558	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000222	0.000554	CcSEcCtD
Mesalazine—Diarrhoea—Vincristine—sarcoma	0.000221	0.000552	CcSEcCtD
Mesalazine—Sweating—Epirubicin—sarcoma	0.000221	0.000551	CcSEcCtD
Mesalazine—Pollakiuria—Doxorubicin—sarcoma	0.000221	0.000551	CcSEcCtD
Mesalazine—Haematuria—Epirubicin—sarcoma	0.000219	0.000548	CcSEcCtD
Mesalazine—Photosensitivity reaction—Doxorubicin—sarcoma	0.000218	0.000545	CcSEcCtD
Mesalazine—Hepatobiliary disease—Epirubicin—sarcoma	0.000218	0.000544	CcSEcCtD
Mesalazine—Weight increased—Doxorubicin—sarcoma	0.000217	0.000543	CcSEcCtD
Mesalazine—Epistaxis—Epirubicin—sarcoma	0.000217	0.000542	CcSEcCtD
Mesalazine—Nausea—Thiotepa—sarcoma	0.000217	0.000541	CcSEcCtD
Mesalazine—Weight decreased—Doxorubicin—sarcoma	0.000216	0.00054	CcSEcCtD
Mesalazine—Sinusitis—Epirubicin—sarcoma	0.000216	0.000539	CcSEcCtD
Mesalazine—Feeling abnormal—Etoposide—sarcoma	0.000216	0.000539	CcSEcCtD
Mesalazine—Diarrhoea—Mitoxantrone—sarcoma	0.000215	0.000538	CcSEcCtD
Mesalazine—Nausea—Dactinomycin—sarcoma	0.000215	0.000537	CcSEcCtD
Mesalazine—Agranulocytosis—Epirubicin—sarcoma	0.000215	0.000536	CcSEcCtD
Mesalazine—Pneumonia—Doxorubicin—sarcoma	0.000214	0.000535	CcSEcCtD
Mesalazine—Gastrointestinal pain—Etoposide—sarcoma	0.000214	0.000535	CcSEcCtD
Mesalazine—Dizziness—Vincristine—sarcoma	0.000214	0.000534	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—sarcoma	0.000213	0.000532	CcSEcCtD
Mesalazine—Infestation—Doxorubicin—sarcoma	0.000213	0.000532	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000211	0.000527	CcSEcCtD
Mesalazine—Renal failure—Doxorubicin—sarcoma	0.000209	0.000523	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—sarcoma	0.000209	0.000521	CcSEcCtD
Mesalazine—Urticaria—Etoposide—sarcoma	0.000208	0.00052	CcSEcCtD
Mesalazine—Haemoglobin—Epirubicin—sarcoma	0.000208	0.000519	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—sarcoma	0.000208	0.000518	CcSEcCtD
Mesalazine—Stomatitis—Doxorubicin—sarcoma	0.000208	0.000518	CcSEcCtD
Mesalazine—Rhinitis—Epirubicin—sarcoma	0.000207	0.000517	CcSEcCtD
Mesalazine—Abdominal pain—Etoposide—sarcoma	0.000207	0.000517	CcSEcCtD
Mesalazine—Body temperature increased—Etoposide—sarcoma	0.000207	0.000517	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—sarcoma	0.000207	0.000517	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—sarcoma	0.000207	0.000517	CcSEcCtD
Mesalazine—Hepatitis—Epirubicin—sarcoma	0.000207	0.000516	CcSEcCtD
Mesalazine—Haemorrhage—Epirubicin—sarcoma	0.000207	0.000516	CcSEcCtD
Mesalazine—Vomiting—Vincristine—sarcoma	0.000206	0.000513	CcSEcCtD
Mesalazine—Pharyngitis—Epirubicin—sarcoma	0.000205	0.000512	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—sarcoma	0.000204	0.00051	CcSEcCtD
Mesalazine—Urinary tract disorder—Epirubicin—sarcoma	0.000204	0.00051	CcSEcCtD
Mesalazine—Rash—Vincristine—sarcoma	0.000204	0.000509	CcSEcCtD
Mesalazine—Dermatitis—Vincristine—sarcoma	0.000204	0.000509	CcSEcCtD
Mesalazine—Oedema peripheral—Epirubicin—sarcoma	0.000204	0.000508	CcSEcCtD
Mesalazine—Haematuria—Doxorubicin—sarcoma	0.000203	0.000507	CcSEcCtD
Mesalazine—Connective tissue disorder—Epirubicin—sarcoma	0.000203	0.000507	CcSEcCtD
Mesalazine—Urethral disorder—Epirubicin—sarcoma	0.000203	0.000506	CcSEcCtD
Mesalazine—Headache—Vincristine—sarcoma	0.000203	0.000506	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—sarcoma	0.000201	0.000503	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—sarcoma	0.000201	0.000502	CcSEcCtD
Mesalazine—Vomiting—Mitoxantrone—sarcoma	0.0002	0.0005	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—sarcoma	0.0002	0.000499	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—sarcoma	0.000199	0.000496	CcSEcCtD
Mesalazine—Rash—Mitoxantrone—sarcoma	0.000199	0.000496	CcSEcCtD
Mesalazine—Dermatitis—Mitoxantrone—sarcoma	0.000198	0.000495	CcSEcCtD
Mesalazine—Headache—Mitoxantrone—sarcoma	0.000197	0.000493	CcSEcCtD
Mesalazine—Erythema multiforme—Epirubicin—sarcoma	0.000195	0.000488	CcSEcCtD
Mesalazine—Eye disorder—Epirubicin—sarcoma	0.000193	0.000482	CcSEcCtD
Mesalazine—Hypersensitivity—Etoposide—sarcoma	0.000193	0.000482	CcSEcCtD
Mesalazine—Tinnitus—Epirubicin—sarcoma	0.000193	0.000481	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—sarcoma	0.000192	0.00048	CcSEcCtD
Mesalazine—Nausea—Vincristine—sarcoma	0.000192	0.00048	CcSEcCtD
Mesalazine—Cardiac disorder—Epirubicin—sarcoma	0.000192	0.000479	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—sarcoma	0.000192	0.000479	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—sarcoma	0.000191	0.000478	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—sarcoma	0.000191	0.000478	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—sarcoma	0.00019	0.000474	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—sarcoma	0.000189	0.000472	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—sarcoma	0.000188	0.00047	CcSEcCtD
Mesalazine—Asthenia—Etoposide—sarcoma	0.000188	0.000469	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—sarcoma	0.000188	0.000469	CcSEcCtD
Mesalazine—Angiopathy—Epirubicin—sarcoma	0.000187	0.000468	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—sarcoma	0.000187	0.000468	CcSEcCtD
Mesalazine—Nausea—Mitoxantrone—sarcoma	0.000187	0.000467	CcSEcCtD
Mesalazine—Immune system disorder—Epirubicin—sarcoma	0.000187	0.000466	CcSEcCtD
Mesalazine—Mediastinal disorder—Epirubicin—sarcoma	0.000186	0.000465	CcSEcCtD
Mesalazine—Chills—Epirubicin—sarcoma	0.000185	0.000463	CcSEcCtD
Mesalazine—Pruritus—Etoposide—sarcoma	0.000185	0.000463	CcSEcCtD
Mesalazine—Alopecia—Epirubicin—sarcoma	0.000183	0.000456	CcSEcCtD
Mesalazine—Mental disorder—Epirubicin—sarcoma	0.000181	0.000452	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—sarcoma	0.000181	0.000451	CcSEcCtD
Mesalazine—Erythema—Epirubicin—sarcoma	0.00018	0.000449	CcSEcCtD
Mesalazine—Diarrhoea—Etoposide—sarcoma	0.000179	0.000448	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—sarcoma	0.000179	0.000446	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—sarcoma	0.000178	0.000445	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—sarcoma	0.000177	0.000443	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—sarcoma	0.000177	0.000443	CcSEcCtD
Mesalazine—Tension—Epirubicin—sarcoma	0.000177	0.000441	CcSEcCtD
Mesalazine—Dysgeusia—Epirubicin—sarcoma	0.000176	0.00044	CcSEcCtD
Mesalazine—Nervousness—Epirubicin—sarcoma	0.000175	0.000436	CcSEcCtD
Mesalazine—Back pain—Epirubicin—sarcoma	0.000174	0.000435	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—sarcoma	0.000173	0.000433	CcSEcCtD
Mesalazine—Dizziness—Etoposide—sarcoma	0.000173	0.000433	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—sarcoma	0.000173	0.000432	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—sarcoma	0.000173	0.000431	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—sarcoma	0.000172	0.00043	CcSEcCtD
Mesalazine—Chills—Doxorubicin—sarcoma	0.000172	0.000428	CcSEcCtD
Mesalazine—Vision blurred—Epirubicin—sarcoma	0.00017	0.000423	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—sarcoma	0.000169	0.000422	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—sarcoma	0.000167	0.000418	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—sarcoma	0.000167	0.000417	CcSEcCtD
Mesalazine—Vomiting—Etoposide—sarcoma	0.000167	0.000416	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—sarcoma	0.000166	0.000416	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—sarcoma	0.000166	0.000415	CcSEcCtD
Mesalazine—Rash—Etoposide—sarcoma	0.000165	0.000412	CcSEcCtD
Mesalazine—Dermatitis—Etoposide—sarcoma	0.000165	0.000412	CcSEcCtD
Mesalazine—Headache—Etoposide—sarcoma	0.000164	0.00041	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—sarcoma	0.000164	0.00041	CcSEcCtD
Mesalazine—Tension—Doxorubicin—sarcoma	0.000163	0.000408	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—sarcoma	0.000163	0.000407	CcSEcCtD
Mesalazine—Malaise—Epirubicin—sarcoma	0.000162	0.000405	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—sarcoma	0.000162	0.000404	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—sarcoma	0.000162	0.000404	CcSEcCtD
Mesalazine—Syncope—Epirubicin—sarcoma	0.000161	0.000403	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—sarcoma	0.000161	0.000402	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—sarcoma	0.000161	0.000402	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—sarcoma	0.00016	0.0004	CcSEcCtD
Mesalazine—Palpitations—Epirubicin—sarcoma	0.000159	0.000397	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—sarcoma	0.000158	0.000395	CcSEcCtD
Mesalazine—Cough—Epirubicin—sarcoma	0.000157	0.000392	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—sarcoma	0.000157	0.000392	CcSEcCtD
Mesalazine—Nausea—Etoposide—sarcoma	0.000156	0.000389	CcSEcCtD
Mesalazine—Hypertension—Epirubicin—sarcoma	0.000155	0.000388	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—sarcoma	0.000154	0.000386	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—sarcoma	0.000154	0.000384	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—sarcoma	0.000153	0.000382	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—sarcoma	0.000153	0.000382	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—sarcoma	0.000153	0.000382	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—sarcoma	0.000153	0.000381	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000152	0.00038	CcSEcCtD
Mesalazine—Discomfort—Epirubicin—sarcoma	0.000151	0.000378	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—sarcoma	0.00015	0.000375	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—sarcoma	0.00015	0.000374	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—sarcoma	0.00015	0.000373	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—sarcoma	0.000149	0.000373	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—sarcoma	0.000149	0.000372	CcSEcCtD
Mesalazine—Confusional state—Epirubicin—sarcoma	0.000148	0.00037	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—sarcoma	0.000147	0.000367	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—sarcoma	0.000147	0.000367	CcSEcCtD
Mesalazine—Oedema—Epirubicin—sarcoma	0.000147	0.000367	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—sarcoma	0.000146	0.000365	CcSEcCtD
Mesalazine—Infection—Epirubicin—sarcoma	0.000146	0.000364	CcSEcCtD
Mesalazine—Cough—Doxorubicin—sarcoma	0.000145	0.000363	CcSEcCtD
Mesalazine—Shock—Epirubicin—sarcoma	0.000144	0.000361	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—sarcoma	0.000144	0.00036	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—sarcoma	0.000144	0.000359	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—sarcoma	0.000144	0.000359	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—sarcoma	0.000143	0.000358	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—sarcoma	0.000143	0.000356	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—sarcoma	0.000142	0.000354	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—sarcoma	0.000142	0.000354	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—sarcoma	0.000142	0.000354	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—sarcoma	0.000142	0.000354	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—sarcoma	0.000141	0.000353	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000141	0.000351	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—sarcoma	0.00014	0.00035	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—sarcoma	0.00014	0.00035	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—sarcoma	0.000139	0.000346	CcSEcCtD
Mesalazine—Hypotension—Epirubicin—sarcoma	0.000137	0.000343	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—sarcoma	0.000137	0.000342	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—sarcoma	0.000136	0.000339	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—sarcoma	0.000136	0.000339	CcSEcCtD
Mesalazine—Infection—Doxorubicin—sarcoma	0.000135	0.000337	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000134	0.000334	CcSEcCtD
Mesalazine—Shock—Doxorubicin—sarcoma	0.000134	0.000334	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—sarcoma	0.000133	0.000333	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—sarcoma	0.000133	0.000332	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—sarcoma	0.000133	0.000332	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—sarcoma	0.000133	0.000331	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—sarcoma	0.000132	0.00033	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—sarcoma	0.000132	0.000329	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—sarcoma	0.000131	0.000328	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—sarcoma	0.000131	0.000327	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—sarcoma	0.000131	0.000326	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—sarcoma	0.000129	0.000323	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—sarcoma	0.000129	0.000323	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—sarcoma	0.000128	0.000319	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—sarcoma	0.000127	0.000317	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—sarcoma	0.000127	0.000317	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—sarcoma	0.000127	0.000316	CcSEcCtD
Mesalazine—Pain—Epirubicin—sarcoma	0.000126	0.000314	CcSEcCtD
Mesalazine—Constipation—Epirubicin—sarcoma	0.000126	0.000314	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000124	0.000309	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—sarcoma	0.000123	0.000307	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—sarcoma	0.000122	0.000305	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—sarcoma	0.000121	0.000302	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—sarcoma	0.000121	0.000302	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—sarcoma	0.000121	0.000302	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—FOXO1—sarcoma	0.00012	0.000404	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PDGFRB—sarcoma	0.00012	0.000404	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Epirubicin—sarcoma	0.00012	0.0003	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB4—HRAS—sarcoma	0.00012	0.000403	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—EGFR—sarcoma	0.00012	0.000403	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL2—sarcoma	0.00012	0.000403	CbGpPWpGaD
Mesalazine—Dyspepsia—Doxorubicin—sarcoma	0.00012	0.000299	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—MDM2—sarcoma	0.000119	0.000402	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—KRAS—sarcoma	0.000119	0.000399	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PDGFRA—sarcoma	0.000118	0.000397	CbGpPWpGaD
Mesalazine—Decreased appetite—Doxorubicin—sarcoma	0.000118	0.000295	CcSEcCtD
Mesalazine—IKBKB—MAPK Signaling Pathway—KRAS—sarcoma	0.000118	0.000397	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000118	0.000395	CbGpPWpGaD
Mesalazine—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000117	0.000293	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—sarcoma	0.000117	0.000292	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	0.000117	0.000394	CbGpPWpGaD
Mesalazine—Urticaria—Epirubicin—sarcoma	0.000117	0.000291	CcSEcCtD
Mesalazine—Pain—Doxorubicin—sarcoma	0.000116	0.00029	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—sarcoma	0.000116	0.00029	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—sarcoma	0.000116	0.00029	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—sarcoma	0.000116	0.00029	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—KRAS—sarcoma	0.000116	0.000388	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—HRAS—sarcoma	0.000115	0.000385	CbGpPWpGaD
Mesalazine—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	0.000114	0.000384	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—HRAS—sarcoma	0.000114	0.000383	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—FOXO1—sarcoma	0.000114	0.000382	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—HRAS—sarcoma	0.000114	0.000382	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—HRAS—sarcoma	0.000113	0.000381	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PDGFRB—sarcoma	0.000113	0.000381	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	0.000113	0.000381	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—HRAS—sarcoma	0.000113	0.000379	CbGpPWpGaD
Mesalazine—Feeling abnormal—Doxorubicin—sarcoma	0.000112	0.00028	CcSEcCtD
Mesalazine—CHUK—Disease—ENO2—sarcoma	0.000112	0.000376	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PDGFRA—sarcoma	0.000112	0.000375	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—sarcoma	0.000111	0.000374	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Doxorubicin—sarcoma	0.000111	0.000277	CcSEcCtD
Mesalazine—IKBKB—B Cell Activation—EGFR—sarcoma	0.000111	0.000373	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—MYC—sarcoma	0.000111	0.000372	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	0.000111	0.000372	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—CREB1—sarcoma	0.00011	0.000368	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—FOXO1—sarcoma	0.000109	0.000367	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PDGFRB—sarcoma	0.000109	0.000366	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL2—sarcoma	0.000109	0.000365	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—EGFR—sarcoma	0.000108	0.000364	CbGpPWpGaD
Mesalazine—Hypersensitivity—Epirubicin—sarcoma	0.000108	0.00027	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—sarcoma	0.000108	0.00027	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000108	0.000362	CbGpPWpGaD
Mesalazine—Body temperature increased—Doxorubicin—sarcoma	0.000107	0.000268	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—sarcoma	0.000107	0.000268	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—PDGFRA—sarcoma	0.000107	0.00036	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—TP53—sarcoma	0.000107	0.000359	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—HRAS—sarcoma	0.000106	0.000357	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	0.000106	0.000357	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—HRAS—sarcoma	0.000106	0.000357	CbGpPWpGaD
Mesalazine—Asthenia—Epirubicin—sarcoma	0.000105	0.000263	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR—HRAS—sarcoma	0.000105	0.000354	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTPRC—sarcoma	0.000105	0.000353	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TP53—sarcoma	0.000105	0.000353	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—KRAS—sarcoma	0.000105	0.000352	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000104	0.000351	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—HRAS—sarcoma	0.000104	0.000351	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—HRAS—sarcoma	0.000104	0.00035	CbGpPWpGaD
Mesalazine—Pruritus—Epirubicin—sarcoma	0.000104	0.000259	CcSEcCtD
Mesalazine—CHUK—Signaling by PDGF—HRAS—sarcoma	0.000104	0.000349	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PLCG1—sarcoma	0.000103	0.000346	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—SRC—sarcoma	0.000103	0.000345	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MMP2—sarcoma	0.000102	0.000343	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—HRAS—sarcoma	0.000101	0.000339	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—NRAS—sarcoma	0.000101	0.000338	CbGpPWpGaD
Mesalazine—Diarrhoea—Epirubicin—sarcoma	0.0001	0.000251	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—TLE1—sarcoma	0.0001	0.000337	CbGpPWpGaD
Mesalazine—Hypersensitivity—Doxorubicin—sarcoma	0.0001	0.00025	CcSEcCtD
Mesalazine—PPARG—Metabolism—ENO2—sarcoma	9.98e-05	0.000335	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—HBA1—sarcoma	9.92e-05	0.000333	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—NRAS—sarcoma	9.88e-05	0.000332	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—HRAS—sarcoma	9.82e-05	0.00033	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ATF1—sarcoma	9.77e-05	0.000328	CbGpPWpGaD
Mesalazine—Asthenia—Doxorubicin—sarcoma	9.75e-05	0.000243	CcSEcCtD
Mesalazine—Dizziness—Epirubicin—sarcoma	9.71e-05	0.000242	CcSEcCtD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	9.63e-05	0.000323	CbGpPWpGaD
Mesalazine—Pruritus—Doxorubicin—sarcoma	9.61e-05	0.00024	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—KIT—sarcoma	9.54e-05	0.000321	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTPRC—sarcoma	9.53e-05	0.00032	CbGpPWpGaD
Mesalazine—CHUK—Disease—PLCG1—sarcoma	9.49e-05	0.000319	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	9.4e-05	0.000316	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	9.39e-05	0.000316	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	9.37e-05	0.000315	CbGpPWpGaD
Mesalazine—Vomiting—Epirubicin—sarcoma	9.33e-05	0.000233	CcSEcCtD
Mesalazine—IKBKB—Immune System—PLCG1—sarcoma	9.32e-05	0.000313	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—SRC—sarcoma	9.32e-05	0.000313	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	9.3e-05	0.000313	CbGpPWpGaD
Mesalazine—Diarrhoea—Doxorubicin—sarcoma	9.29e-05	0.000232	CcSEcCtD
Mesalazine—Rash—Epirubicin—sarcoma	9.26e-05	0.000231	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—sarcoma	9.25e-05	0.000231	CcSEcCtD
Mesalazine—Headache—Epirubicin—sarcoma	9.2e-05	0.00023	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—KIT—sarcoma	9.16e-05	0.000308	CbGpPWpGaD
Mesalazine—CHUK—Disease—CXCR4—sarcoma	9.12e-05	0.000307	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—NRAS—sarcoma	9.12e-05	0.000306	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—sarcoma	9.09e-05	0.000306	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TLE1—sarcoma	9.09e-05	0.000306	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CREB1—sarcoma	9.08e-05	0.000305	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—EGFR—sarcoma	9.01e-05	0.000303	CbGpPWpGaD
Mesalazine—Dizziness—Doxorubicin—sarcoma	8.98e-05	0.000224	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—NRAS—sarcoma	8.96e-05	0.000301	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—HRAS—sarcoma	8.91e-05	0.000299	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ATF1—sarcoma	8.86e-05	0.000298	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CREB1—sarcoma	8.72e-05	0.000293	CbGpPWpGaD
Mesalazine—Nausea—Epirubicin—sarcoma	8.72e-05	0.000218	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—KIT—sarcoma	8.65e-05	0.000291	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—KRAS—sarcoma	8.65e-05	0.000291	CbGpPWpGaD
Mesalazine—Vomiting—Doxorubicin—sarcoma	8.64e-05	0.000216	CcSEcCtD
Mesalazine—Rash—Doxorubicin—sarcoma	8.56e-05	0.000214	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—sarcoma	8.56e-05	0.000214	CcSEcCtD
Mesalazine—Headache—Doxorubicin—sarcoma	8.51e-05	0.000213	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—KRAS—sarcoma	8.51e-05	0.000286	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TLE1—sarcoma	8.48e-05	0.000285	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PLCG1—sarcoma	8.47e-05	0.000285	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFC—sarcoma	8.46e-05	0.000284	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	8.41e-05	0.000283	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KIT—sarcoma	8.31e-05	0.000279	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CREB1—sarcoma	8.24e-05	0.000277	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	8.19e-05	0.000275	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—EGFR—sarcoma	8.17e-05	0.000274	CbGpPWpGaD
Mesalazine—Nausea—Doxorubicin—sarcoma	8.07e-05	0.000202	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—CREB1—sarcoma	7.91e-05	0.000266	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—KRAS—sarcoma	7.85e-05	0.000264	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—CTNNB1—sarcoma	7.82e-05	0.000263	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—KRAS—sarcoma	7.71e-05	0.000259	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFC—sarcoma	7.67e-05	0.000258	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NPM1—sarcoma	7.65e-05	0.000257	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	7.53e-05	0.000253	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MDM2—sarcoma	7.52e-05	0.000253	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	7.37e-05	0.000248	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HRAS—sarcoma	7.35e-05	0.000247	CbGpPWpGaD
Mesalazine—CHUK—Immune System—FOXO1—sarcoma	7.3e-05	0.000245	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PDGFRB—sarcoma	7.28e-05	0.000245	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—HRAS—sarcoma	7.23e-05	0.000243	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—MDM2—sarcoma	7.22e-05	0.000243	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PDGFRA—sarcoma	7.17e-05	0.000241	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—SRC—sarcoma	7.07e-05	0.000238	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ENO2—sarcoma	6.99e-05	0.000235	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	6.96e-05	0.000234	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HBA1—sarcoma	6.95e-05	0.000233	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—VEGFA—sarcoma	6.88e-05	0.000231	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MDM2—sarcoma	6.82e-05	0.000229	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—NRAS—sarcoma	6.8e-05	0.000229	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FLT1—sarcoma	6.76e-05	0.000227	CbGpPWpGaD
Mesalazine—CHUK—Disease—FOXO1—sarcoma	6.74e-05	0.000226	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—MYC—sarcoma	6.73e-05	0.000226	CbGpPWpGaD
Mesalazine—CHUK—Disease—PDGFRB—sarcoma	6.72e-05	0.000226	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HRAS—sarcoma	6.67e-05	0.000224	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PLCG1—sarcoma	6.65e-05	0.000223	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ENO2—sarcoma	6.63e-05	0.000223	CbGpPWpGaD
Mesalazine—CHUK—Disease—PDGFRA—sarcoma	6.62e-05	0.000222	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FOXO1—sarcoma	6.61e-05	0.000222	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PDGFRB—sarcoma	6.6e-05	0.000222	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—HRAS—sarcoma	6.56e-05	0.00022	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—MDM2—sarcoma	6.54e-05	0.00022	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—JUN—sarcoma	6.53e-05	0.00022	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PDGFRA—sarcoma	6.5e-05	0.000218	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CTNNB1—sarcoma	6.48e-05	0.000218	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCR4—sarcoma	6.39e-05	0.000215	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ATF1—sarcoma	6.31e-05	0.000212	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EGFR—sarcoma	6.19e-05	0.000208	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	6.19e-05	0.000208	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FLT1—sarcoma	6.13e-05	0.000206	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PLCG1—sarcoma	6.03e-05	0.000203	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PLCG1—sarcoma	5.93e-05	0.000199	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—JUN—sarcoma	5.92e-05	0.000199	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CTNNB1—sarcoma	5.88e-05	0.000198	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—SRC—sarcoma	5.86e-05	0.000197	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—sarcoma	5.85e-05	0.000197	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCR4—sarcoma	5.79e-05	0.000195	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ATF1—sarcoma	5.73e-05	0.000192	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NRAS—sarcoma	5.64e-05	0.000189	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—SRC—sarcoma	5.63e-05	0.000189	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PLCG1—sarcoma	5.62e-05	0.000189	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KIT—sarcoma	5.56e-05	0.000187	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ENO2—sarcoma	5.55e-05	0.000187	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HBA1—sarcoma	5.51e-05	0.000185	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NRAS—sarcoma	5.41e-05	0.000182	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CXCR4—sarcoma	5.4e-05	0.000182	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—SRC—sarcoma	5.31e-05	0.000179	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CREB1—sarcoma	5.29e-05	0.000178	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—sarcoma	5.14e-05	0.000173	CbGpPWpGaD
Mesalazine—CHUK—Disease—KIT—sarcoma	5.13e-05	0.000172	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NRAS—sarcoma	5.11e-05	0.000172	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—SRC—sarcoma	5.1e-05	0.000171	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KIT—sarcoma	5.04e-05	0.000169	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—sarcoma	4.97e-05	0.000167	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1R—sarcoma	4.96e-05	0.000167	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—sarcoma	4.93e-05	0.000166	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NRAS—sarcoma	4.91e-05	0.000165	CbGpPWpGaD
Mesalazine—CHUK—Disease—CREB1—sarcoma	4.89e-05	0.000164	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—sarcoma	4.85e-05	0.000163	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CREB1—sarcoma	4.8e-05	0.000161	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FOXO1—sarcoma	4.72e-05	0.000159	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PLCG1—sarcoma	4.71e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PDGFRB—sarcoma	4.71e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—sarcoma	4.66e-05	0.000157	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—sarcoma	4.66e-05	0.000157	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PDGFRA—sarcoma	4.63e-05	0.000156	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1R—sarcoma	4.49e-05	0.000151	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—sarcoma	4.47e-05	0.00015	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—sarcoma	4.4e-05	0.000148	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MDM2—sarcoma	4.38e-05	0.000147	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FOXO1—sarcoma	4.28e-05	0.000144	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PDGFRB—sarcoma	4.27e-05	0.000143	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—sarcoma	4.22e-05	0.000142	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PDGFRA—sarcoma	4.2e-05	0.000141	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—sarcoma	4.12e-05	0.000139	CbGpPWpGaD
Mesalazine—CHUK—Disease—MDM2—sarcoma	4.04e-05	0.000136	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FOXO1—sarcoma	3.99e-05	0.000134	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PDGFRB—sarcoma	3.98e-05	0.000134	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MDM2—sarcoma	3.97e-05	0.000133	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—sarcoma	3.96e-05	0.000133	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PDGFRA—sarcoma	3.92e-05	0.000132	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—sarcoma	3.91e-05	0.000131	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KDR—sarcoma	3.9e-05	0.000131	CbGpPWpGaD
Mesalazine—CHUK—Immune System—JUN—sarcoma	3.81e-05	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CTNNB1—sarcoma	3.78e-05	0.000127	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—sarcoma	3.74e-05	0.000126	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KIT—sarcoma	3.59e-05	0.000121	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—sarcoma	3.59e-05	0.000121	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—sarcoma	3.55e-05	0.000119	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KDR—sarcoma	3.54e-05	0.000119	CbGpPWpGaD
Mesalazine—CHUK—Disease—CTNNB1—sarcoma	3.49e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—JUN—sarcoma	3.45e-05	0.000116	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTNNB1—sarcoma	3.42e-05	0.000115	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CREB1—sarcoma	3.42e-05	0.000115	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SRC—sarcoma	3.41e-05	0.000115	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—sarcoma	3.28e-05	0.00011	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KIT—sarcoma	3.26e-05	0.00011	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—sarcoma	3.24e-05	0.000109	CbGpPWpGaD
Mesalazine—CHUK—Disease—SRC—sarcoma	3.15e-05	0.000106	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CREB1—sarcoma	3.1e-05	0.000104	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SRC—sarcoma	3.09e-05	0.000104	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KIT—sarcoma	3.04e-05	0.000102	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—sarcoma	3.03e-05	0.000102	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—sarcoma	2.99e-05	0.000101	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—sarcoma	2.98e-05	0.0001	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CREB1—sarcoma	2.89e-05	9.73e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MDM2—sarcoma	2.83e-05	9.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—sarcoma	2.83e-05	9.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—sarcoma	2.82e-05	9.49e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—sarcoma	2.76e-05	9.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—sarcoma	2.71e-05	9.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—sarcoma	2.61e-05	8.77e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MDM2—sarcoma	2.57e-05	8.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—sarcoma	2.56e-05	8.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—sarcoma	2.53e-05	8.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—sarcoma	2.47e-05	8.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JUN—sarcoma	2.46e-05	8.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CTNNB1—sarcoma	2.44e-05	8.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—sarcoma	2.4e-05	8.07e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MDM2—sarcoma	2.39e-05	8.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—sarcoma	2.29e-05	7.71e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—sarcoma	2.24e-05	7.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JUN—sarcoma	2.23e-05	7.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—sarcoma	2.22e-05	7.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNB1—sarcoma	2.21e-05	7.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SRC—sarcoma	2.21e-05	7.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—sarcoma	2.18e-05	7.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—sarcoma	2.15e-05	7.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—sarcoma	2.12e-05	7.14e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CTNNB1—sarcoma	2.07e-05	6.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SRC—sarcoma	2e-05	6.73e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—sarcoma	1.98e-05	6.65e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—sarcoma	1.95e-05	6.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—sarcoma	1.93e-05	6.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—sarcoma	1.93e-05	6.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SRC—sarcoma	1.87e-05	6.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—sarcoma	1.83e-05	6.14e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—sarcoma	1.8e-05	6.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—sarcoma	1.79e-05	6.03e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—sarcoma	1.75e-05	5.89e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—sarcoma	1.67e-05	5.62e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—sarcoma	1.66e-05	5.57e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—sarcoma	1.64e-05	5.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—sarcoma	1.62e-05	5.46e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—sarcoma	1.55e-05	5.22e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—sarcoma	1.55e-05	5.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—sarcoma	1.47e-05	4.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—sarcoma	1.41e-05	4.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—sarcoma	1.31e-05	4.42e-05	CbGpPWpGaD
